COMMUNIQUÉS West-GlobeNewswire

-
AI in Breast Imaging: New BreastCT.com Article Examines IzoView’s Competitive Edge
25/09/2025 -
Solid Biosciences to Present at 2025 Neuromuscular Study Group Annual Scientific Meeting
25/09/2025 -
Hyperion DeFi Adds $10M in HYPE to its Treasury Holdings
25/09/2025 -
Biolinq Shine™ Granted De Novo Classification by U.S. FDA for the First Fully Autonomous, Needle-Free Glucose Sensor
25/09/2025 -
Kestra Showcases Cardiac Recovery System Platform at HFSA 2025, Redefining Sudden Cardiac Arrest Risk Management
25/09/2025 -
Numab Therapeutics Achieves Milestone in Collaboration with Boehringer Ingelheim
25/09/2025 -
Predictive Oncology Announces 1-for-15 Reverse Stock Split
25/09/2025 -
Chicago's New Prenatal Education and Social Club Helps Parents Build Their Village
25/09/2025 -
Counterpart Assistant Gets Conversational
25/09/2025 -
Tiziana to Advance TZLS-501 - Its Fully Human IL-6R Monoclonal Antibody
25/09/2025 -
Commure Partners with Bethany Children’s Health Center to Help Reduce Clinician Documentation Burden and Enhance Productivity
25/09/2025 -
Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion
25/09/2025 -
Nexalin Technology Announces Issuance of U.S. Patent Covering HALO™ Clarity Device Featuring DIFS™ Technology
25/09/2025 -
RenovoRx’s PanTheR Post-Marketing Registry Study Progresses with First Clinical Procedure and Addition of Two Participating Clinical Sites
25/09/2025 -
CytoDyn to Present on Leronlimab Induction of PD-L1 and Immune Checkpoint Inhibitor Responses in Metastatic Triple-Negative Breast Cancer at the AACR Special Conference: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity
25/09/2025 -
LB Pharmaceuticals Strengthens Board of Directors with Appointments of William Kane and Rekha Hemrajani
25/09/2025 -
Moleculin Announces Notice of Allowance for Canadian Patent Covering Annamycin
25/09/2025 -
AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen® (Rintatolimod) with Checkpoint Inhibitors
25/09/2025 -
Silexion Therapeutics Regains Compliance with Nasdaq Listing Requirements
25/09/2025
Pages